# Panitumumab, Cisplatin, and Pelvic Radiation Therapy in Treating Patients With Stage IB, Stage II, or Stage III Cervical Cancer

> **NCT01158248** · PHASE2 · UNKNOWN · sponsor: **Medical University Innsbruck** · enrollment: 50 (estimated)

## Conditions studied

- Cervical Cancer

## Interventions

- **BIOLOGICAL:** panitumumab
- **DRUG:** cisplatin
- **RADIATION:** brachytherapy
- **RADIATION:** external beam radiation therapy

## Key facts

- **NCT ID:** NCT01158248
- **Lead sponsor:** Medical University Innsbruck
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-02
- **Primary completion:** 2013-03
- **Final completion:** —
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2010-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01158248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01158248, "Panitumumab, Cisplatin, and Pelvic Radiation Therapy in Treating Patients With Stage IB, Stage II, or Stage III Cervical Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01158248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*